Printer Friendly

VIAGENE FILES FOR AN INITIAL PUBLIC OFFERING

 SAN DIEGO, Jan. 26 /PRNewswire/ -- Viagene, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of 2,500,000 shares of common stock. All of the shares are being sold by the company. The shares are being offered by an underwriting group managed by the First Boston Corporation, Prudential Securities Incorporated and Nomura Securities, Inc. The public offering price is anticipated to be between $11 and $13 per share.
 The company plans to use the net proceeds of the offering for research and development, working capital and other corporate purposes.
 Viagene is a biopharmaceutical company pursuing the discovery, development, and manufacture of gene transfer drugs for the treatment of severe viral infections, cancers and other diseases.
 Copies of the preliminary prospectus relating to the offering may be obtained from the First Boston Corporation, Municipal Securities Division, 55 E. 52nd Street, New York, NY 10055, 212-909-3220; Prudential Securities Incorporated, 315 Hudson Street, 7th Floor, New York, NY 10013, 212-776-8906; and Nomura Securities International, Inc., 2 World Financial Center, Building B, New York, NY 10281, 212-667-1803.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This statement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
 -0- 1/26/93
 /CONTACT: R. Jefferson Works, vice president and chief financial officer of Viagene, Inc., 619-452-1288, or Anthony J. Russo, Ph.D., of Noonan/Russo Communication, 212-979-9180, for Viagene, Inc./


CO: Viagene, Inc. ST: California IN: MTC SU: OFR

SH-OS -- NY010 -- 8936 01/26/93 09:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 26, 1993
Words:332
Previous Article:TERRA INDUSTRIES DISCONTINUES NON-AGRIBUSINESS OPERATIONS & ADOPTS NEW ACCOUNTING STANDARDS; REPORTS FOURTH QUARTER AND FULL YEAR EARNINGS
Next Article:BANCO COMERCIAL PORTUGUES NET INCOME UP 13.6 PERCENT IN 1992
Topics:


Related Articles
AFFYMAX FILES FOR INITIAL PUBLIC OFFERING
CHEMTRAK INCORPORATED FILES INITIAL PUBLIC OFFERING
SYNAPTIC PHARMACEUTICAL FILES FOR INITIAL PUBLIC OFFERING OF COMMON STOCK; NAME CHANGED FROM NEUROGENETIC CORPORATION
FDA GRANTS VIAGENE FIRST COMMERCIAL IND FOR GENE-BASED THERAPEUTIC FOR AIDS
HUMAN CLINICAL TRIALS OF VIAGENE'S GENE TRANSFER THERAPEUTIC FOR AIDS CLEARED BY FDA ADVISORY COMMITTEE
NIH PANEL APPROVES HUMAN TESTING OF WORLD'S FIRST DIRECTLY INJECTABLE GENE-TRANSFER DRUG TO FIGHT AIDS
VIAGENE COMPLETES INITIAL PUBLIC OFFERING
VIAGENE, INC. REPORTS FOURTH QUARTER AND YEAR END RESULTS
LA JOLLA PHARMACEUTICAL CO. FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING OF PUBLIC STOCK

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters